Biggest moves
Q2 2026, quarter ended Jun 30Baker Bros. added $353.6M of Revolution Medicines in Q2 2026.
Shares up 20%. The stake was $2.1B at Jun 30.
Free on iOS and Android
Email me when Baker Bros. Advisors files
FREE. An email the day each 13F is filed, with what was bought and sold. About four a year.
Check your inbox
We sent a link to your address. Tap it to confirm; we email nothing until you do.
Want it the moment it is filed? The app sends a push, free.
Baker Bros. added $353.6M of Revolution Medicines in Q2 2026.
Shares up 20%. The stake was $2.1B at Jun 30.
in 84 positions.
+14.6% filing to filing, from price moves and buying or selling: not the fund’s return. Not investment advice.
Assets under management, as reported to the SEC
$28.1BRegulatory assets under management on Form ADV, filed Mar 27, 2026 by Baker Bros. Advisors LP. A gross figure: it counts borrowed money and assets a 13F never lists, so it is not the 13F value.
13F stock positions at the latest close
$21.7B+9.2% on the $19.9B of stock lines filed for Jun 30
If unchanged since Jun 30, 2026: the filing's stock lines at the Nov 12 close. Options and bonds left out; 99.4% of the value priced, the rest carried at its filed value. An estimate of what the filed positions are worth now, not a forecast and not the fund's return. How it is made. Not investment advice.
Faeth Therapeutics is the one new position among the 15 largest moves. Worth $32.2M at Jun 30.
positions sold out among the 15 largest moves. Worth $233.7M together at Mar 31, the quarter before.
Incyte is the largest, at 17.5% of the 13F value. The five largest are 52.0%.
| Holding | Type | Value | Shares | % of 13F value |
|---|---|---|---|---|
| INCYIncyte | Shares | $3.5B | 30,762,330 shares | 17.5% |
| ONCBeOne Medicines AG | Shares | $2.5B | 8,801,567 shares | 12.6% |
| RVMDRevolution Medicines | Shares | $2.1B | 11,443,357 shares | 10.7% |
| MDGLMadrigal Pharmaceuticals | Shares | $1.2B | 2,143,131 shares | 5.8% |
| ACADAcadia Pharmaceuticals | Shares | $1.1B | 42,912,904 shares | 5.4% |
| KYMRKymera Therapeutics | Shares | $992.7M | 8,657,242 shares | 5.0% |
| INSMInsmed | Shares | $937.8M | 8,796,111 shares | 4.7% |
| CELCCelcuity | Shares | $828.2M | 7,915,792 shares | 4.2% |
| KODKodiak Sciences | Shares | $776.1M | 19,919,186 shares | 3.9% |
| RYTMRhythm Pharmaceuticals | Shares | $622.3M | 5,604,483 shares | 3.1% |
| PRAXPraxis Precision Medicines | Shares | $587.0M | 1,753,198 shares | 2.9% |
| ALKSAlkermes | Shares | $524.6M | 10,012,267 shares | 2.6% |
| SMMTSummit Therapeutics | Shares | $477.7M | 32,786,348 shares | 2.4% |
| GRALGRAIL | Shares | $275.0M | 4,028,614 shares | 1.4% |
| ABCLAbCellera Biologics | Shares | $259.1M | 33,012,138 shares | 1.3% |
| IMVTImmunovant | Shares | $209.4M | 5,435,220 shares | 1.0% |
| IDYAIDEAYA Biosciences | Shares | $186.7M | 5,010,030 shares | 0.9% |
| KNSAKiniksa Pharmaceuticals International | Shares | $181.3M | 2,834,643 shares | 0.9% |
| ROIVRoivant Sciences | Shares | $166.9M | 4,716,831 shares | 0.8% |
| ARWRArrowhead Pharmaceuticals | Shares | $162.4M | 1,992,783 shares | 0.8% |
| IONSIonis Pharmaceuticals | Shares | $162.4M | 2,047,727 shares | 0.8% |
| EWTXEdgewise Therapeutics | Shares | $150.4M | 3,701,719 shares | 0.8% |
| REPLReplimune Group | Shares | $122.3M | 11,045,336 shares | 0.6% |
| NRIXNurix Therapeutics | Shares | $113.0M | 4,658,556 shares | 0.6% |
| STOKStoke Therapeutics | Shares | $109.2M | 3,336,697 shares | 0.5% |
| GLUEMonte Rosa Therapeutics | Shares | $105.2M | 4,345,736 shares | 0.5% |
| IMTXImmatics | Shares | $96.3M | 9,508,565 shares | 0.5% |
| DNLIDenali Therapeutics | Shares | $96.0M | 3,734,336 shares | 0.5% |
| CRNXCrinetics Pharmaceuticals | Shares | $88.0M | 2,351,465 shares | 0.4% |
| DNTHDianthus Therapeutics | Shares | $83.1M | 852,164 shares | 0.4% |
| GPCRStructure Therapeutics | Shares | $76.9M | 1,432,529 shares | 0.4% |
| Celcuity | Note | $69.2M | n/a | 0.3% |
| RAPPRapport Therapeutics | Shares | $64.5M | 1,547,090 shares | 0.3% |
| ALMSAlumis | Shares | $56.6M | 2,012,500 shares | 0.3% |
| PRLDPrelude Therapeutics | Shares | $54.0M | 10,123,824 shares | 0.3% |
| RLAYRelay Therapeutics | Shares | $52.9M | 2,826,783 shares | 0.3% |
| MIRMMirum Pharmaceuticals | Shares | $52.2M | 445,975 shares | 0.3% |
| BCYCBicycle Therapeutics | Shares | $46.2M | 10,885,357 shares | 0.2% |
| ELVNEnliven Therapeutics | Shares | $45.9M | 905,191 shares | 0.2% |
| CLDXCelldex Therapeutics | Shares | $44.0M | 1,182,611 shares | 0.2% |
| VRDNViridian Therapeutics | Shares | $43.8M | 2,383,025 shares | 0.2% |
| DSGNDesign Therapeutics | Shares | $38.8M | 2,678,430 shares | 0.2% |
| TRDAEntrada Therapeutics | Shares | $37.3M | 5,072,730 shares | 0.2% |
| SNSEFaeth Therapeutics | Shares | $32.2M | 1,286,411 shares | 0.2% |
| AKTSAktis Oncology | Shares | $32.1M | 996,351 shares | 0.2% |
| NGNENeurogene | Shares | $31.2M | 991,691 shares | 0.2% |
| JBIOJade Biosciences | Shares | $27.3M | 1,230,426 shares | 0.1% |
| TSHATaysha Gene Therapies | Shares | $27.3M | 4,004,756 shares | 0.1% |
| RCUSArcus Biosciences | Shares | $26.0M | 844,816 shares | 0.1% |
| IRONDisc Medicine | Shares | $25.6M | 349,657 shares | 0.1% |
% of 13F value is the position's value against the whole disclosed 13F value, so the rows shown here do not sum to 100% unless every position is listed. A Note is a convertible bond, which the filing sizes by its face amount rather than a share count.
| Holding | Move | Share change | Est. amount moved | Value after |
|---|---|---|---|---|
| RVMDRevolution Medicines | Added | +19.8% | +$353.6M | $2.1B after |
| INSMInsmed | Added | +18.5% | +$146.6M | $937.8M after |
| EWTXEdgewise Therapeutics | Trimmed | -43.7% | -$116.8M | $150.4M after |
| ABVXAbivax | Exited | -100% | -$97.5M | $0 after |
| SMMTSummit Therapeutics | Trimmed | -9.9% | -$52.5M | $477.7M after |
| SYRESpyre Therapeutics | Exited | -100% | -$50.4M | $0 after |
| IDYAIDEAYA Biosciences | Added | +26.9% | +$39.6M | $186.7M after |
| SNSEFaeth Therapeutics | New | new | +$32.2M | $32.2M after |
| RLAYRelay Therapeutics | Added | +143.7% | +$31.2M | $52.9M after |
| CNTACentessa Pharmaceuticals | Exited | -100% | -$26.6M | $0 after |
| IMCRImmunocore Holdings | Exited | -100% | -$22.1M | $0 after |
| ABCLAbCellera Biologics | Added | +9.0% | +$21.5M | $259.1M after |
| CLDXCelldex Therapeutics | Added | +77.7% | +$19.2M | $44.0M after |
| CTNMContineum Therapeutics | Exited | -100% | -$18.6M | $0 after |
| ARGXargenx SE | Exited | -100% | -$18.4M | $0 after |
A change is this filing measured against the one before it. Est. amount moved is the shares added or sold, priced at the Jun 30, 2026 close. An estimate: a 13F gives no trade prices or dates. For a sold-out position, its value at the previous quarter end.
Source: Form 13F, filed with the SEC on Aug 14, 2026, for positions held on Jun 30, 2026. A 13F lists US-listed stock and options at their quarter-end value; short sales, cash and most bonds are not in it. Methodology · Guide to Form 13F. Checked for newer filings on Nov 14, 2026. Not investment advice.
What Baker Bros. Advisors holds, what moved and how current the filing is.
Baker Bros. Advisors disclosed 84 positions worth $20.0B in the Q2 2026 13F filing. The largest is INCY at 17.5% of the disclosed value. A 13F lists US-listed stock and options on it; short sales and cash are not in it.
Comparing the Q2 2026 filing with the quarter before, the largest moves were adding to RVMD, adding to INSM, trimming EWTX and selling out of ABVX. Changes are measured against the previous filing, not against trades, because a 13F does not disclose trades.
This is the Q2 2026 filing, covering positions held on Jun 30, 2026 and filed with the SEC on Aug 14, 2026. A 13F is due 45 days after the quarter ends, so the most recent filing is always at least six weeks behind the market, and the manager may have changed the book since.